Overview
DRTS market data
Price History
DRTS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.53 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.00 – $14.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 5.47.
Company News
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16Benzinga · Aug 11, 2026, 2:58 PM
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) EstimateBenzinga · Aug 10, 2026, 8:39 PM
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price TargetBenzinga · Jul 22, 2026, 4:09 PM
Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable PatientsBenzinga · Jul 21, 2026, 12:34 PM
Alpha Tau Medical Treats First Patient In ADMIRE Study, Clinical Trial Evaluating Intratumoral Alpha DaRT For Immunocompromised Patients With Recurrent Cutaneous Squamous Cell CarcinomaBenzinga · Jul 15, 2026, 12:35 PM
Alpha Tau Medical Announces Success Treatment With Alpha DaRT Of First Glioblastoma Patient In IsraelBenzinga · Jun 23, 2026, 12:40 PM
Alpha Tau Medical Receives FDA Clearance To Proceed With Enrollment Of Final Seven Patients In U.S. REGAIN TrialBenzinga · Jun 11, 2026, 12:33 PM
Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $17Benzinga · Jun 4, 2026, 1:01 PM
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On WednesdayBenzinga · Jun 3, 2026, 3:25 PM
Alpha Tau Medical shares are trading lower. The company announced overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound-guided intratumoral Alpha DaRT treatment in patients with pancreatic ductal adenocarcinoma.Benzinga · Jun 1, 2026, 3:04 PM